Myosin Therapeutics Inc.
Jupiter, FL Myosin Therapeutics, Inc.
- UEI
- MLH1HUK133H3
- CAGE
- 8SNG6
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 130 Scripps Way, Jupiter, FL 33458, USA
- Website
- myosintherapeutics.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Development of drug product to support a phase 0/1B dose escalation trial of MT-125 in recurrent high grade gliomas -… | National Cancer Institute | $249,417 | |
| Phase 0/1B clinical trial of novel therapeutic agent MT-110 for the reduction of methamphetamine use - part 2 -… | National Institute on Drug Abuse | $2,916,991 | |
| Phase 0/i dose escalation trial of MT-125 monotherapy in recurrent high-grade gliomas - project summary an area of… | National Cancer Institute | $2,245,802 | |
| MT-125 for the therapeutic treatment of glioblastoma - project summary an area of significant unmet need is the… | National Cancer Institute | $10,020,186 | |
| Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse - project… | National Institute on Drug Abuse | $6,690,392 |
About Myosin Therapeutics Inc.
Myosin Therapeutics Inc. is a corporate entity registered in SAM.gov, specializing in developing innovative pharmaceutical compounds targeting complex medical conditions, with a focus on neurological and substance use disorders. Located in Jupiter, Florida, the company concentrates on creating small molecule inhibitors that target molecular motor proteins, specifically non-muscle myosin II, to address challenging therapeutic areas with significant unmet medical needs. The company's primary research and development efforts are centered on developing novel drug candidates like MT-125 for glioblastoma treatment and MT-110 for methamphetamine use disorder, demonstrating a strategic approach to developing targeted therapeutic interventions.
The federal grant awards received by Myosin Therapeutics Inc. highlight its commitment to advancing therapeutic solutions in critical medical domains. The company has secured multiple project grants from prominent federal agencies, including the National Cancer Institute and the National Institute on Drug Abuse. These grants, totaling approximately $3.2 million, support advanced clinical research for two primary drug candidates: MT-125 for treating recurrent high-grade gliomas and MT-110 for reducing methamphetamine use disorder. The grants fund Phase 0/1B and Phase 1B clinical trials, focusing on developing innovative treatments for aggressive brain cancers and substance use disorders. The research emphasizes unique therapeutic approaches, such as targeting non-muscle myosin II molecular motors to suppress cellular invasion and proliferation, and developing interventions that can restore brain structural plasticity and reduce drug-seeking behaviors. These federal awards underscore Myosin Therapeutics' scientific expertise in developing potentially transformative pharmacological treatments for complex medical conditions.
Quick answers
What is Myosin Therapeutics Inc.'s UEI?
Myosin Therapeutics Inc.'s Unique Entity ID (UEI) in SAM.gov is MLH1HUK133H3.
What is Myosin Therapeutics Inc.'s CAGE code?
Myosin Therapeutics Inc.'s CAGE code is 8SNG6.
Where is Myosin Therapeutics Inc. located?
Myosin Therapeutics Inc.'s physical address in SAM.gov is 130 Scripps Way, Jupiter, FL 33458, USA.
Is Myosin Therapeutics Inc. registered in SAM.gov?
Yes. Myosin Therapeutics Inc.'s SAM.gov registration is active through January 7, 2027.
What is Myosin Therapeutics Inc.'s most recent federal award?
Myosin Therapeutics Inc.'s most recent federal grant award is Development of drug product to support a phase 0/1B dose escalation trial of MT-125 in recurrent high grade gliomas -… (SB1CA302068), from National Cancer Institute, on September 1, 2025.
On GovTribe
See Myosin Therapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors